DrugPatentWatch Database Preview

Details for Patent: 9,145,389

« Back to Dashboard

Which drugs does patent 9,145,389 protect, and when does it expire?

Patent 9,145,389 protects DEXILANT and DEXILANT SOLUTAB and is included in two NDAs.

This patent has forty-nine patent family members in twenty-five countries.

Summary for Patent: 9,145,389

Title:	Benzimidazole compound crystal
Abstract:	A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
Inventor(s):	Fujishima; Akira (Hyogo, JP), Aoki; Isao (Hyogo, JP)
Assignee:	Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:	14/508,651
Patent Claim Types: see list of patent claims	Compound; Formulation; Composition;

Drugs Protected by US Patent 9,145,389

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-001	Jan 30, 2009		RX	Yes	No			Y	Y
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-002	Jan 30, 2009	AB	RX	Yes	Yes			Y	Y
Takeda Pharms Usa	DEXILANT SOLUTAB	dexlansoprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	208056-001	Jan 26, 2016		DISCN	Yes	No			Y	Y

Foreign Priority and PCT Information for Patent: 9,145,389

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	11-171509	Jun 17, 1999

International Family Members for US Patent 9,145,389

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	031069
Argentina	079473
Argentina	093609
Argentina	100473